Pharmafile Logo

News and Press Releases

Medable Reports 80% Revenue Growth from Portfolio-Level eCOA Adoption, Sharp Increase Compared to Study-by-Study Adoption

Growing industry confidence drives shift in digital strategy for clinical trial sponsors 28 January 2025 -- California, US -- Medable Inc., a leading provider of clinical development technology, today announced 80%...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

WCG Launches ClinSphere™ Total Enrollment: An All-New Participant Recruitment and Retention SaaS Solution for Clinical Trials

27 January 2025 -- New Jersey, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of ClinSphere™ Total Enrollment. This...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 28, 2025

WCG Clinical
info@wcgclinical.com
212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Protas launches novel unified clinical trial management platform, Cantata

27 January 2025 -- London, UK -- Protas, a not-for-profit organisation transforming the design and delivery of large clinical trials, announces the launch of its unified clinical trial management platform,...

Category: Clinical Trials, Drug Discovery, Other
Posted: January 27, 2025

Protas

Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025

Pfizer
235 East 42nd Street NY, NY 10017

Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment

Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025

ANGLE plc
2 Occam Court, Occam Road, Surrey Research Park, Guilford, GU2 7QB

Medidata and Tigermed Renew Strategic Partnership Aimed at Accelerating Clinical Trials Globally

Extended partnership will enhance study efficiency and regulatory compliance, leveraging Medidata’s platform to improve access to new therapies 23 January 2025 -- New York, US -- Medidata, a Dassault Systèmes brand...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 23, 2025

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine

VE303 was well tolerated and decreased the odds of rCDI through multiple mechanisms Analyses identified predictors of VE303 colonization and protection from CDI recurrence Topline data for the ongoing Phase...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: January 23, 2025

Vedanta Biosciences
info@vedantabio.com
19 Blackstone Street Cambridge, MA 02139

European Commission approves LAZCLUZE®▼ (lazertinib) in combination with RYBREVANT®▼ (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 21, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Opella reaches study milestone for Cialis

21 January 2025 -- Paris, France -- Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual...

Category: Clinical Trials, Other, Pharmaceutical
Posted: January 21, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials

9 January 2025 -- Cambridge, UK and Montreal, Canada -- Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 9, 2025

Biofidelity
5151 McCrimmon Parkway, Suite 230 Morrisville, NC 27560

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)

Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025

PureTech Health
info@puretechhealth.com
PureTech Health 6 Tide Street Boston, MA 02210